Overview
Mentions in press and media 5
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 1, 2024 | $18M grant investigates Cognitive decline in Lewy body diseases | PHILADELPHIA—Penn Medicine researchers will advance their understanding of the underlying causes of cognitive decline in individuals with Lewy body diseases, like Parkinson’s, and identify biomarkers that predict which individuals are more ... |
| Jun 16, 2023 | The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab | Over the past several months, my conversations with colleagues in the Alzheimer’s field have featured an unusual sentiment: optimism inflected with worry. Optimism because, after years of failed studies and the disastrous accelerated approv... |
| Dec 6, 2019 | Aducanumab: the beginning of the end of Alzheimer’s disease? | In histories written about Alzheimer’s disease, 2019 will turn up as a landmark year, one in which researchers, clinicians, patients, and their families were whipsawed from crushing despair to giddy optimism. The year unfolded with a string... |
| Jul 17, 2019 | It’s time to change the definition of ‘health’ | Meet Betty, a typical aging American. At 82, she spends almost as much time with her doctors as she does with her grandchildren. She has to. She takes seven prescription medications to treat her high blood pressure, high cholesterol, diabet... |
Reviews 0
FAQ about Penn Memory Center
What has the press written about Penn Memory Center?
Parsers VC has collected 5 articles mentioning Penn Memory Center, among them “$18M grant investigates Cognitive decline in Lewy body diseases” (Oct 1, 2024) and “The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab” (Jun 16, 2023).
Is Penn Memory Center still active?
Penn Memory Center is probably closed: its latest activity on Parsers VC dates from Jan 22, 2025.